 |
|
Comparative Trial of HPV-77, DE-5 and RA 27/3 Live-Attenuated Rubella Vaccines
Robert B. Wallace, MD;
Peter Isacson, MD
Am J Dis Child. 1972;124(4):536-538.
Abstract
An experimental live, attenuated rubella vaccine, RA 27/3, was compared with HPV-77, DE-5 rubella vaccine (Meruvax) in children in an open school setting. Seroconversion of RA 27/3 vaccines administered by either intranasal or subcutaneous route and HPV-77, DE-5 given subcutaneously was 95% or greater as measured by hemagglutination-inhibition antibody (HI). However, RA 27/3 vaccine produced significantly greater seroconversion rates and titer levels by complement-fixation antibody (CF) testing, when compared with HPV-77, DE-5 vaccine. No serious reactions were noted, and there were no joint reactions in any study group during the 28-day postimmunization follow-up period or upon recontacting vaccine recipients one year later. Intranasal immunization was well tolerated.
Author Affiliations
Buffalo, NY
From the Vaccine Evaluation Unit, Department of Social and Preventive Medicine, State University of New York at Buffalo, and the Center for Disease Control, Public Health Service, Atlanta. Drs. Wallace and Isacson are currently at the Department of Preventive Medicine and Environmental Health, College of Medicine, University of Iowa, Iowa City.
Footnotes
Received for publication Dec 13, 1971; accepted April 7, 1972.
Reprint requests to the Department of Preventive Medicine and Environmental Health, College of Medicine, University of Iowa, Iowa City 52240 (Dr. Wallace).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Rubella Virus Immunization of Preschool Children via the Respiratory Tract
Ganguly et al.
Arch Pediatr Adolesc Med 1974;128:821-823.
ABSTRACT
|
